Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542695 · ClinicalTrials.gov registry record · Early Phase 1
64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy
A Early Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 1
- Enrollment target
NCT03542695 is a Early Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 1 participants.
The verdict
NCT03542695, a Early Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This early phase I pilot trial studies how well 64Cu-DOTA-alendronate positron emission tomography (PET) imaging work in localizing and characterizing breast calcifications (small calcium deposits) in participants before undergoing mastectomy. Diagnostic procedures, such 64Cu-DOTA-alendronate PET, may detect calcification and help doctors predict cancer associated calcification within breast tissue.
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Positron Emission Tomography
- OTHER Pharmacokinetic Study
- DRUG Copper Cu-64-DOTA-alendronate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2024-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542695
The ClinicalTrials.gov registry entry for NCT03542695 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Computed Tomography is the first listed.
NCT03542695 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542695 about?
NCT03542695 is a clinical study titled "64 Cu-DOTA-alendronate PET Imaging in Localizing and Characterizing Breast Calcifications in Participants Before Undergoing Mastectomy". This early phase I pilot trial studies how well 64Cu-DOTA-alendronate positron emission tomography (PET) imaging work in localizing and characterizing breast calcifications (small calcium deposits) in participants before undergoing mastectomy. Diagnostic procedures, such 64Cu-DOTA-alendronate PET, m...
What is the current status of trial NCT03542695?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2021-11-03. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT03542695?
The interventions under investigation include: Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Pharmacokinetic Study (OTHER), Copper Cu-64-DOTA-alendronate (DRUG).
Who is sponsoring clinical trial NCT03542695?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.